Illumina Countersues IBS, Qiagen for Infringement of Sequencing Patents

from GenomeWeb News

Illumina has countersued Intelligent Bio-Systems and Qiagen, claiming they infringe several of its sequencing-related patents, the company said today.

The suit follows several weeks after Qiagen acquired IBS, and a few months after Columbia University sued Illumina in March for allegedly infringing five sequencing patents licensed by IBS.

In counterclaims related to that suit, Illumina alleges that IBS and Qiagen infringe three of its patents — US Patent Nos. 7,057,026; 7,785,796; and 8,158,346; all entitled “Labelled Nucleotides” and all expiring in December 2022.

(read more at GenomeWeb…)